Přejít k obsahu
Merck
Všechny fotografie(1)

Key Documents

View All Documentation

Y0001517

Haloperidol for system suitability

European Pharmacopoeia (EP) Reference Standard

Synonyma:

Haloperidol, 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone, 4-[4-(4-Chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone, 4-[4-(p-Chlorophenyl)-4-hydroxypiperidino]-4′-fluorobutyrophenone

Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
Všechny fotografie(1)

About This Item

Empirický vzorec (Hillův zápis):
C21H23ClFNO2
Číslo CAS:
52-86-8
Molekulová hmotnost:
375.86
MDL number:
MFCD00051423
UNSPSC Code:
41116107
PubChem Substance ID:
329831468
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

haloperidol

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

OC1(CCN(CCCC(=O)c2ccc(F)cc2)CC1)c3ccc(Cl)cc3

InChI

1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2

InChI key

LNEPOXFFQSENCJ-UHFFFAOYSA-N

Gene Information

human ... HTR2A(3356)

Hledáte podobné produkty? Navštivte Průvodce porovnáváním produktů

Související kategorie

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Haloperidol for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Č. produktu
Popis
Stanovení ceny

H0100000

Haloperidol, European Pharmacopoeia (EP) Reference Standard

1303002

Haloperidol, United States Pharmacopeia (USP) Reference Standard

H0100100

Haloperidol decanoate, European Pharmacopoeia (EP) Reference Standard

Y0001518

Haloperidol for peak identification, European Pharmacopoeia (EP) Reference Standard

1303013

Haloperidol Related Compound A, United States Pharmacopeia (USP) Reference Standard

1303057

Haloperidol decanoate, United States Pharmacopeia (USP) Reference Standard

1303024

Haloperidol Related Compound B, United States Pharmacopeia (USP) Reference Standard

PHR1724

Haloperidol, Pharmaceutical Secondary Standard; Certified Reference Material

BP407

Haloperidol, British Pharmacopoeia (BP) Reference Standard

PHR8951

Haloperidol Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR8714

Haloperidol Related Compound B, certified reference material, pharmaceutical secondary standard

pictograms

Skull and crossbonesHealth hazard
GHS06,GHS08

signalword

Danger

Hazard Classifications

Acute Tox. 3 Oral - Eye Irrit. 2 - Repr. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3

target_organs

Respiratory system

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Vyberte jednu z posledních verzí:

Osvědčení o analýze (COA)

Lot/Batch Number

Je nám líto, ale pro tento produkt momentálně nemáme COA k dispozici online.

Potřebujete-li pomoc, obraťte se na Zákaznická podpora

Již tento produkt vlastníte?

Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.

Navštívit knihovnu dokumentů

Mark C Fok et al.
International journal of geriatric psychiatry, 30(4), 333-344 (2015-02-03)
To summarize the effect of antipsychotics for preventing postoperative delirium. We conducted a literature search using Medline, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews and clinicaltrials.gov. We included randomized controlled trials of adults undergoing surgery
Robin Nguyen et al.
The Journal of neuroscience : the official journal of the Society for Neuroscience, 34(45), 14948-14960 (2014-11-08)
Hyperactivity within the ventral hippocampus (vHPC) has been linked to both psychosis in humans and behavioral deficits in animal models of schizophrenia. A local decrease in GABA-mediated inhibition, particularly involving parvalbumin (PV)-expressing GABA neurons, has been proposed as a key
Marianne Klemp et al.
Journal of clinical psychopharmacology, 31(6), 698-704 (2011-10-25)
The objective of the study was to examine the efficacy and the degree of adverse effects connected with atypical neuroleptic drugs and haloperidol by using a previously described Bayesian statistical method that includes both direct and indirect comparisons simultaneously. The
Paul Perkins et al.
The Cochrane database of systematic reviews, (2)(2), CD006271-CD006271 (2009-04-17)
Nausea and vomiting are common symptoms of patients with terminal, incurable illnesses and can be distressing. The primary objective of the review was to evaluate the efficacy and adverse events associated with the use of haloperidol for the treatment of
Lorna Donnelly et al.
The Cochrane database of systematic reviews, 8(8), CD001951-CD001951 (2013-08-29)
Haloperidol is a benchmark, accessible antipsychotic drug against which the effects of newer treatments are gauged. To determine the best range of doses for haloperidol for the treatment of people acutely ill with schizophrenia. We searched the Cochrane Schizophrenia Group
Zobrazit všechny související dokumenty

Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..

Obraťte se na technický servis.